Competitor launches oral GLP-1 weight-loss pill within 12 months
Resolves: A competitor (non-Novo Nordisk) publicly announces or makes available a new oral GLP-1 weight-loss pill for prescription or private sale in the UK market by 2027-07-06.
user-generated· adoption
Competitor launches oral GLP-1 weight-loss pill within 12 months
Market overview
At least one major pharmaceutical competitor (e.g., Eli Lilly, Pfizer, or Amgen) will launch an oral GLP-1 weight-loss pill within 12 months, targeting Novo Nordisk’s market lead.
adoption prediction market
- Implied probability (Yes)
- 55%
- Closes
- 2027-07-06
About this prediction
Resolution criteria
A competitor (non-Novo Nordisk) publicly announces or makes available a new oral GLP-1 weight-loss pill for prescription or private sale in the UK market by 2027-07-06.
Source: user-generated
More adoption markets
- Daily active crypto users surpass 100 million by mid-2026 — 60% Yes
- Kalshi’s market share in crypto derivatives surpasses 5% by Q4 2027 — 55% Yes
- Kalshi's crypto perpetual futures launch by 2026-Q4 — 75% Yes
- Family offices double down on crypto-adjacent mining firms within 6 months — 72% Yes
- Nigeria's crypto transaction volume exceeds $5B in 2026 — 80% Yes
- AI and crypto groups increase political ad spending in 2026 midterms — 80% Yes
- Crypto and AI groups double political ad spending by 2027 — 75% Yes
- Crypto billionaire Harborne will increase donations to Farage by 20% by Mar 2027 — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…